For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Astute Medical, Inc.

USPTO Granted Patents = 53

% Expired Patents = 30.2

CIPO Patents = 3

EPO Patents = 44

Trademarks = 7

Forward Citations = 197

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Paul H McPherson (43 out of 69 patents)

Joseph Anderberg (38 out of 46 patents)

Jeff Gray (36 out of 54 patents)

4. Kevin Nakamura (36 out of 36 patents)

5. James Patrick Kampf (28 out of 39 patents)

6. Ravi A Vijayendran (8 out of 8 patents)

7. Thomas Kwan (6 out of 15 patents)

8. Srivatsa Venkatasubbarao (6 out of 7 patents)

9. John Alston Kellum (4 out of 26 patents)

10. Donald Chalfin (2 out of 2 patents)

11. Hua Wang (2 out of 3 patents)

12. John Van Bosch (2 out of 5 patents)

13. Lakhmir S Chawla (1 out of 21 patents)

14. Alexander Zarbock (1 out of 1 patent)

15. Kai Singbartl (9 patents)

Core Competencies:

Renal Injury

Prognosis

Diagnosis

Assays

CCL14

TIMP2

IGFBP7

Acute Kidney Injury

Biological Samples

Follistatin

Insulin-like Growth Factor

Stroke

53 patents: Sort by Forward Citations

1. 12655205 - ANTIBODIES AND ASSAYS FOR CCL14 (2026-06-16),

2. 12624121 - ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES (2026-05-12),

3. 12203944 - Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement (2025-01-21),

4. 12203941 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2025-01-21),

5. 12123882 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-10-22),

6. 12099067 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-09-24),

7. 12019080 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-06-25),

8. 11891439 - Antibodies and assays for CCL14 (2024-02-06),

9. 11761967 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2023-09-19),

10. 11754566 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2023-09-12),

11. 11718682 - Assays for TIMP2 having improved performance in biological samples (2023-08-08),

12. 11506672 - Follistatin-related protein 3 for diagnosis and prognosis of renal injury and renal failure (2022-11-22),

13. 11454635 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-09-27),

14. 11353465 - Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement (2022-06-07),

15. 11346846 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-05-31),

Company Overview

Astute Medical, Inc., based in San Diego, CA, specializes in renal diagnostics, focusing on the early detection and prognosis of acute kidney injury (AKI). The company develops innovative assays that leverage biomarkers such as CCL14, TIMP2, and IGFBP7 to enhance the diagnosis and management of renal conditions. By advancing the understanding of renal injury mechanisms, Astute Medical aims to improve patient outcomes through timely and accurate diagnostic solutions in the healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

53 Patents

#117 in San Diego, CA

#1,566 in California

#6,670 in US

#13,334 in the World

San Diego, CA, United States of America

Astute Medical, Inc.

Forward Citations = 197

14 inventors:

Paul H McPherson (43 out of 69 patents)

Joseph Anderberg (38 out of 46 patents)

Jeff Gray (36 out of 54 patents)

4. Kevin Nakamura (36 out of 36 patents)

5. James Patrick Kampf (28 out of 39 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Astute Medical, Inc.. Retrieved from https://idiyas.com/company/astute-medical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…